Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Eli Lilly and Company
Bernhard Ludvik; Francesco Giorgino; Esteban Jódar; Juan P Frias; Laura Fernández Landó; Katelyn Brown; Ross Bray; Ángel Rodríguez